181 related articles for article (PubMed ID: 37031341)
21. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
[TBL] [Abstract][Full Text] [Related]
22. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
23. Altered redox regulation and S-glutathionylation of BiP contribute to bortezomib resistance in multiple myeloma.
Zhang J; Ye ZW; Chen W; Culpepper J; Jiang H; Ball LE; Mehrotra S; Blumental-Perry A; Tew KD; Townsend DM
Free Radic Biol Med; 2020 Nov; 160():755-767. PubMed ID: 32937189
[TBL] [Abstract][Full Text] [Related]
24. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
25. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
26. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
27. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
Marchica V; Accardi F; Storti P; Mancini C; Martella E; Dalla Palma B; Bolzoni M; Todoerti K; Marcatti M; Schifano C; Bonomini S; Sammarelli G; Neri A; Ponzoni M; Aversa F; Giuliani N
Int J Hematol; 2017 Jan; 105(1):104-108. PubMed ID: 27699576
[TBL] [Abstract][Full Text] [Related]
29. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
[TBL] [Abstract][Full Text] [Related]
30. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.
Ghasemi M; Alpsoy S; Türk S; Malkan ÜY; Atakan Ş; Haznedaroğlu İC; Güneş G; Gündüz M; Yılmaz B; Etgül S; Aydın S; Aslan T; Sayınalp N; Aksu S; Demiroğlu H; Özcebe OI; Büyükaşık Y; Göker H
Turk J Haematol; 2016 Dec; 33(4):286-292. PubMed ID: 27095044
[TBL] [Abstract][Full Text] [Related]
31. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
32. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
33. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
[TBL] [Abstract][Full Text] [Related]
34. Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease.
Zatopkova M; Filipová J; Jelínek T; Vojta P; Sevcikova T; Simicek M; Rihova L; Bezdekova R; Growkova K; Kufová Z; Smejkalová J; Hajdúch M; Pour L; Minárik J; Jungová A; Maisnar V; Kryukov F; Hájek R
Klin Onkol; 2017; 30(Supplementum2):75-80. PubMed ID: 28903574
[TBL] [Abstract][Full Text] [Related]
35. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
[TBL] [Abstract][Full Text] [Related]
36. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
37. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.
Wen Z; Rajagopalan A; Flietner ED; Yun G; Chesi M; Furumo Q; Burns RT; Papadas A; Ranheim EA; Pagenkopf AC; Morrow ZT; Finn R; Zhou Y; Li S; You X; Jensen J; Yu M; Cicala A; Menting J; Mitsiades CS; Callander NS; Bergsagel PL; Wang D; Asimakopoulos F; Zhang J
Blood; 2021 Jan; 137(1):61-74. PubMed ID: 32640012
[TBL] [Abstract][Full Text] [Related]
38. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
39. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
[TBL] [Abstract][Full Text] [Related]
40. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
